Your browser doesn't support javascript.
loading
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
Pouyiourou, Maria; Kraft, Bianca N; Wohlfromm, Timothy; Stahl, Michael; Kubuschok, Boris; Löffler, Harald; Hacker, Ulrich T; Hübner, Gerdt; Weiss, Lena; Bitzer, Michael; Ernst, Thomas; Schütt, Philipp; Hielscher, Thomas; Delorme, Stefan; Kirchner, Martina; Kazdal, Daniel; Ball, Markus; Kluck, Klaus; Stenzinger, Albrecht; Bochtler, Tilmann; Krämer, Alwin.
Afiliação
  • Pouyiourou M; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Kraft BN; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Wohlfromm T; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University of Heidelberg, Heidelberg, Germany.
  • Stahl M; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Kubuschok B; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Löffler H; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Hacker UT; Department of Medical Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany.
  • Hübner G; Department of Internal Medicine II, Augsburg University Medical Center and Bavarian Cancer Research Center (BZKF), Partner Cite Augsburg, Augsburg, Germany.
  • Weiss L; Department of Internal Medicine III, Marienhospital Stuttgart, Stuttgart, Germany.
  • Bitzer M; Department of Medicine II, University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Leipzig, Germany.
  • Ernst T; Department of Internal Medicine III, Ameos Krankenhausgesellschaft Ostholstein, Eutin, Germany.
  • Schütt P; Department of Internal Medicine, Comprehensive Cancer Center, University of Munich, Munich, Germany.
  • Hielscher T; Department of Gastroenterology, Hepatology and Infectiology, University Hospital Tübingen, Tübingen, Germany.
  • Delorme S; Department of Internal Medicine II, Jena University Hospital, Jena, Germany.
  • Kirchner M; Onkologische Gemeinschaftspraxis, Gütersloh, Germany.
  • Kazdal D; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Ball M; Division of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Kluck K; Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
  • Stenzinger A; Center for Personalized Medicine (ZPM), University of Heidelberg, Heidelberg, Germany.
  • Bochtler T; Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
  • Krämer A; Center for Personalized Medicine (ZPM), University of Heidelberg, Heidelberg, Germany.
Nat Commun ; 14(1): 6761, 2023 10 24.
Article em En | MEDLINE | ID: mdl-37875494
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Primárias Desconhecidas / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Primárias Desconhecidas / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha